Oragenics, Inc. OGEN 深 滬
已收盤 09-19 16:00:00 美东时间
1.19
-0.020
-1.65%
華盛通- 最 高1.28
- 今 開1.24
- 成交量 10.24万股
- 最 低 1.19
- 昨 收 1.21
- 總市值 491.14万
- 52周最高 18.897
- 市盈率 靜 --
- 換手率 2.48%
- 52周最低 1.01
- 委 比 -12.65%
- 總股本 412.72万
- 歷史最高 83700.00
- 量 比 0.54
- 振 幅 7.44%
- 歷史最低 1.19
- 每 手 1
- 風險率 1.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CHARBONE Hydrogen announces $2M convertible debentures replacement
CHARBONE HYDROGEN (TSXV:CH:CA) announced on Thursday the signature of replacement debentures of an amount of $2.05M by amending certain terms of the secured convertible debentures of the company that ...
09-19 13:32
哈密通慧德向国富氢能下单1.5亿元绿氢设备采购合同
2025年8月18日，国富氢能全资控股公司新疆国富铭志氢能科技有限责任公司（以下简称 “国富铭志”）与哈密通慧德绿色铸造有限公司（以下简称 “哈密通慧德”）在哈...
08-19 08:33
Oragenics Q2 2025 Shareholder Update
Oragenics, Inc. has achieved significant milestones in developing ONP-002, aiming to become the first FDA-approved pharmacological treatment for concussion. The company's proprietary intranasal delivery technology offers rapid brain delivery, bypassing systemic circulation, and is expected to initiate Phase IIa trials in Q3 2025. Key achievements include human research ethics committee approval, partnerships with Southern Star Research and Sterli...
08-11 12:45
Neogen Chemicals Reports Resilient Q1 FY26 Performance
Neogen Chemicals Ltd. ( ($IN:NEOGEN) ) just unveiled an update. Neogen Chemical...
08-03 03:25
Oragenics Selects Southern Star Research As Clinical Research Organization For Upcoming Phase IIa Clinical Trial Of ONP-002, Lead Drug Candidate For Concussion
Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, today announced the selection of Southern Star Research as its Clinical Research
07-31 20:37
国富氢能首套出口马来西亚国家电网绿氢电解水系统成功发运
GREEN HYDROGEN 近日，国富氢能为马来西亚国家电网TNB - PCSS绿氢示范项目供应的50方水电解产品，已顺利发运至上海港，标志着国富...
07-22 14:31
Oragenics Enters Manufacturing Agreement With Sterling Pharma For GMP Production Of Concussion Drug, ONP-002
Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an
07-16 20:41
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
Oragenics, a biotech company developing intranasal therapeutics for brain-related conditions, has partnered with Sterling Pharma Solutions for GMP production of its lead drug candidate, ONP-002, to treat concussions. This collaboration aims to support planned Phase IIb clinical trials starting next year. The partnership underscores Oragenics' commitment to quality, efficiency, and U.S.-based innovation, while Sterling's expertise in CNS therapies...
07-16 12:39
“痛风”鏖战：西方不亮东方亮？
（转自：氨基观察） 当高尿酸血症以1.77亿患病人数成为我国“第四高”，现有治疗药物却仍深陷局限困局。 非布司他心血管风险争议如影随形，苯溴马隆肝毒性隐患挥之...
07-14 11:11
Oragenics Raises $16.5M Through Public Offering
Oragenics ( ($OGEN) ) has issued an announcement. On July 1, 2025, Oragenics, I...
07-03 04:45
